Amgen Inc. convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG’s Sandoz Inc until 2028.
https://www.pharmalive.com/wp-content/uploads/2020/10/Osteoporosis-drug-helps-Amgen-third-quarter-profit-beat-estimates-Reuters-10-28-20.jpeg246370Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-04-19 17:38:352023-04-19 20:40:51U.S. Amgen ruling keeps generic psoriasis drug off market until 2028
